| Literature DB >> 16724057 |
John D Benson1, Ying-Nan P Chen, Susan A Cornell-Kennon, Marion Dorsch, Sunkyu Kim, Magdalena Leszczyniecka, William R Sellers, Christoph Lengauer.
Abstract
A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.Entities:
Mesh：
Year: 2006 PMID： 16724057 DOI： 10.1038/nature04873
Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962